When is a Generic Version of Axert (axitinib) Expected?
Axitinib’s main patent protection in the United States expires in 2028, giving generic manufacturers a window to file for approval after that date. The FDA typically allows a “patent dance” where competitors can seek to challenge exclusivity, so the earliest a generic could be approved is likely late 2028 or early 2029, depending on any legal challenges and the FDA’s review timeline.
Which Patents Guard Axert?
The key patents cover the drug’s active ingredient, formulation, and method of use for renal cell carcinoma and hepatocellular carcinoma. These patents are held by Pfizer and its affiliates. In addition to the primary patents, secondary claims related to dosing schedules and combination therapies extend protection through 2028.
Who Is Likely to Make a Generic Axert?
Large specialty drug companies that have successfully developed other tyrosine‑kinase inhibitors—such as Pfizer’s generics arm, Teva, or Mylan—are expected to target Axert once exclusivity ends. Smaller biosimilar producers may also enter the market, especially if they can secure a cost advantage.
How Does Generic Axert Compare in Price?
When the generic enters, it is projected to be 30‑40 % cheaper than the branded price. The exact discount will depend on the number of competitors and their production costs. Early estimates suggest a generic price of roughly $3,500–$4,000 per month versus $5,500–$6,000 for the branded drug.
What Conditions Does Axert Treat?
Axitinib is approved for advanced renal cell carcinoma after progression on sunitinib or sorafenib, and for hepatocellular carcinoma that is sorafenib‑naïve. Its mechanism—selective inhibition of vascular endothelial growth factor receptors (VEGFR) 1‑3—reduces tumor angiogenesis.
How Does Axert Stack Up Against Other VEGFR Inhibitors?
Clinical trials show axitinib offers a higher objective response rate than sorafenib in renal cancer, but it also carries a higher risk of hypertension and hand‑foot syndrome. Compared to pazopanib, axitinib tends to have a shorter half‑life, requiring twice‑daily dosing.
What Side Effects Are Most Common?
Patients often report hypertension, proteinuria, diarrhea, and fatigue. Severe adverse events like bleeding or cardiac events are rare but possible, especially in older patients with pre‑existing cardiovascular disease.
Will Biosimilars Be Possible Before Patent Expiry?
Because axitinib is a small‑molecule inhibitor rather than a biologic, the term “biosimilar” does not apply. However, generic competitors can launch once the patents expire unless a legal challenge extends exclusivity.
What Does DrugPatentWatch Report?
DrugPatentWatch tracks the status of Axert’s patents and predicts that the first generic approval will likely arrive in late 2028, after the expiry of the key U.S. patents. The site highlights potential litigation that could delay entry by up to a year.
DrugPatentWatch – Axert Patent Status